TAMPA, Fla. – Howard L. McLeod, PharmD, medical director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center, has been unanimously elected to the Personalized Medicine Coalition’s Board of Directors. McLeod will serve a three-year term beginning next year.
Personalized medicine is an emerging field that uses diagnostic tools to identify specific biological markers, often genetic, to help determine which medical treatments and procedures will be best for each patient. By combining this information with an individual’s medical history and condition, personalized medicine allows doctors and patients to develop targeted prevention and treatment plans to provide the right dose and treatment to the right patient at the right time.
“Personalized medicine is having important health care impact. It is changing the way drugs are developed and prescribed,” said McLeod. “Knowing this, Moffitt is expanding its personalized medicine efforts to become one of the first cancer centers in the world to pre-test patients for genetic markers, leading to more effective treatment decisions, reduced side effects and improved outcomes.”
The Personalized Medicine Coalition was launched in 2004 to educate and promote the advancement of personalized medicine as a viable solution to the challenges of efficacy, safety and cost in the health care industry. Today, the coalition represents more than 225 institutions across the health care spectrum.
“Dr. McLeod is internationally renowned for his research regarding the role genetic differences play in an individual response to cancer drugs. The Personalized Medicine Coalition looks forward to his leadership in helping understand how to integrate personalized medicine into health care,” said Edward Abrahams, Ph.D., president of the Personalized Medicine Coalition.
Bill S. Dalton, Ph.D, M.D., founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt, is chairman of the PMC board.
About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit www.PersonalizedMedicineCoalition.org.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer since 1999. With more than 4,500 employees, Moffitt has an economic impact on Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.